They need to partner this thing for sure. The returns may be spectacular if successful, but the phIII will cost $30m+ and the risk of failure could set back gains from Cardiocel for years. Then, as evil pointed out, the cost of manufacture and distribution would be enormous. The only question is when to partner, not if. I gather they are looking at doing that after the phII which I think is the best risk return from here.
HSV vaccine Phase 1 Results?, page-14
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.20 |
Change
-0.800(5.71%) |
Mkt cap ! $279.0M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.00 | $13.11 | $947.2K | 71.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |